Pfizer (PFE) Aktievy
Pfizer Inc. upptäcker, utvecklar, tillverkar, marknadsför, distribuerar och säljer biofarmaceutiska produkter i USA och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 2/6 |
| Utdelningar | 4/6 |
Belöningar
Riskanalys
PFE Community Fair Values
Create NarrativeSee what 913 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Pfizer Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$25.90 |
| 52 veckors högsta | US$28.75 |
| 52 veckors lägsta | US$23.06 |
| Beta | 0.31 |
| 1 månads förändring | -4.07% |
| 3 månaders förändring | -4.29% |
| 1 års förändring | 11.06% |
| 3 års förändring | -31.12% |
| 5 års förändring | -33.13% |
| Förändring sedan börsintroduktionen | 5,615.87% |
Senaste nyheter och uppdateringar
Recent updates
Seeking Alpha • May 18
Why Pfizer Stock Still Looks Deeply Undervalued In 2026
Summary Marty Makary resigned from his position as FDA Commissioner on May 12, in my view, in part because of his inconsistent policy approach. The FDA leadership shake-up continues to this day, but as I'll explain below, this period of uncertainty isn't creating pressure on Big Pharma players, including Pfizer. By the way, Pfizer is still my favorite in the oncology drugs market, trading at a non-GAAP P/E ratio of 8.6x and a high 6.8% dividend yield. In Q1, Padcev sales were $591 million, up 16.3% QoQ and 38.7% YoY, mainly due to increased demand for its use in combination with Merck's Keytruda for treatment of MIBC. Next, I'llpresent five more key factors explaining why I continue to cover Pfizer with a'Strong Buy' rating. Read the full article on Seeking Alpha
Uppdatering av berättelse • May 03
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post Settlement Outlook
Pfizer's updated analyst price target has shifted slightly lower to $24.00 from $25.00 as analysts factor in a steeper projected revenue decline, a modestly higher profit margin outlook, and mixed views on the post-settlement pipeline and patent overhang. Analyst Commentary Recent research on Pfizer highlights a split view.
Uppdatering av berättelse • Apr 19
PFE: GLP-1 And Oncology Advancements Will Support Post LOE Repricing
Pfizer's analyst fair value estimate has been adjusted modestly higher to $35.96 from $35.33, as analysts factor in recent price target raises and mixed views on the post-2028 pipeline, loss of exclusivity risks, and evolving expectations for the GLP-1 and oncology portfolios. Analyst Commentary Recent Street research on Pfizer reflects a split view, with some firms expressing caution around patent expiries and near term visibility, while other bullish analysts focus on the potential in GLP-1 and oncology programs, along with broader sector appeal in healthcare.Uppdatering av berättelse • Apr 05
PFE: Obesity And Oncology Pipeline Progress Will Drive Post LOE Rerating
Analysts have nudged Pfizer's implied fair value modestly higher to about $35.33 per share, citing recent price target increases of around $1 to $3 and research that highlights contributions from its GLP-1, oncology, and hematology pipelines, while also noting the long-term patent cliff and revenue uncertainty. Analyst Commentary Recent research on Pfizer shows a split view, with some firms highlighting long term headwinds from loss of exclusivity while others point to pipeline depth and business development as potential offsets.Uppdatering av berättelse • Mar 22
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post 2028 Outlook
Pfizer's updated analyst narrative keeps fair value steady at $25.00, with recent Street research showing price targets clustering from $25.00 to $35.00 as analysts weigh concerns about a post-2028 patent cliff against interest in the GLP-1, oncology, and collaboration pipelines, as well as healthcare's perceived appeal in a riskier macro backdrop. Analyst Commentary Recent Street research around Pfizer reflects a split view, with some firms pointing to potential in GLP-1, oncology, hematology, and collaborations, while others emphasize the scale and timing of the expected revenue cliff and limited visibility on offsets.Uppdatering av berättelse • Mar 08
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Next Decade
Analysts lifted their fair value estimate for Pfizer from $23.00 to $25.00 per share, reflecting updated views that weigh a stronger GLP 1 and oncology pipeline against ongoing concerns about the patent cliff and near term revenue visibility. Analyst Commentary Recent Street research on Pfizer presents a mixed picture, with more cautious voices focusing on patent expirations, limited near term pipeline visibility, and questions around how quickly new therapies can support growth.Uppdatering av berättelse • Feb 21
PFE: Obesity Pipeline Progress Will Drive Post LOE Re Rating
Pfizer's updated analyst price target edges lower to about $35 per share. This reflects analysts' focus on ongoing losses of exclusivity, a slightly softer revenue and margin outlook, and tempered expectations for future P/E as some firms initiate or assume coverage with more cautious views around the next few years.Uppdatering av berättelse • Feb 07
PFE: Obesity Pipeline And LOE Headwinds Will Shape Future Re Rating
Narrative Update Analysts have trimmed their fair value estimate for Pfizer from $36.16 to $35.46, reflecting more cautious assumptions on revenue trends and profit margins, even as some on the Street highlight new assets and deals that they believe could support a higher future P/E multiple. Analyst Commentary Recent Street research on Pfizer highlights a mix of caution and optimism, with several firms reassessing how the pipeline and recent deals might offset upcoming patent expiries and support the valuation over time.Uppdatering av berättelse • Jan 24
PFE: Loss Of Exclusivity And Obesity Deal Costs Will Pressure Shares
Analysts have reduced their fair value estimate for Pfizer from $24.00 to $23.00 per share, citing lower revenue and margin assumptions, a slightly higher discount rate, and cautious views on patent expiries, while still noting ongoing interest in its pipeline and licensing deals. Analyst Commentary Recent Street research around Pfizer has been mixed, with some firms highlighting long term opportunities in areas like obesity and licensing, while others are stressing near term execution and patent expiry risks.Uppdatering av berättelse • Jan 10
PFE: Obesity Deal And LOE Overhang Will Shape Re Rating Potential
Analysts have trimmed their price expectations for Pfizer, citing ongoing revenue uncertainty around an expected US$15b to US$20b loss of exclusivity over the next few years, even as some see support from the obesity deal and a broader positive stance on large cap biopharma. Analyst Commentary Recent research highlights a split view on Pfizer, with some caution around the expected US$15b to US$20b loss of exclusivity over the next few years and others pointing to potential upside linked to obesity treatments and a broader positive stance on large cap biopharma.Analysartikel • Jan 08
Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43
Pfizer Inc. ( NYSE:PFE ) will pay a dividend of $0.43 on the 6th of March. This makes the dividend yield 6.8%, which...Uppdatering av berättelse • Dec 25
PFE: Obesity Bid And Margin Outlook May Drive Re-Rating Ahead
Analysts have nudged their price target on Pfizer higher by $2 to $30, citing improving margin expectations and a more constructive sector backdrop, despite tempered revenue growth assumptions. Analyst Commentary Bullish analysts highlight that the latest price target increase reinforces a gradually improving sentiment toward Pfizer, with investors starting to look past the near term revenue slowdown and focus more on medium term cash flow durability and pipeline execution.Analysartikel • Dec 18
Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43
The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will pay a dividend of $0.43 per share on the 6th of March...
Uppdatering av berättelse • Dec 11
PFE: Obesity Pipeline Expansion Will Drive Upside Amid Sector Rerating
Analysts nudged their price target on Pfizer higher to $30 from $28, citing a sector wide rerating on benign U.S. drug pricing developments and the strategic upside from an expanded obesity pipeline and broader large cap biopharma innovation. Analyst Commentary Bullish analysts highlight that Pfizer is benefiting from a constructive shift in U.S. drug pricing expectations and a broader rerating of large cap biopharma, which supports the recent price target increase and stabilizes valuation multiples.Uppdatering av berättelse • Nov 13
PFE: Obesity Deal Will Drive Upside After Sector Underperformance And Portfolio Shifts
Pfizer’s analyst price target was raised from $28 to $30 per share, reflecting a modest increase in fair value. Analysts cite sector-wide re-rating and updated fundamentals, including acquisition activity and anticipated drug pipeline developments, as key drivers for the revision.Analysartikel • Aug 12
Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business
NYSE:PFE 1 Year Share Price vs Fair Value Explore Pfizer's Fair Values from the Community and select yours Pfizer...Seeking Alpha • Apr 30
Pfizer's Q1 Update May Mark A Bottom In The Stock
Summary Pfizer is facing some revenue pressures due to some higher Medicare discounts, and this has led to a small miss on revenue delivery in Q1 FY25. Pfizer is making meaningful improvements on profitability and is on track to realize a ~12.3% margin lift from 2024 until the end of 2027 from various cost saving initiatives. Stopping R&D of an obesity drug that had $10 billion annual revenue potential is a major setback and if PFE tries M&A instead, there is a risk of overpaying again. PFE stock is trading at trough valuations and at a larger-than-usual discount vs peers. So I think there is some decent margin of safety. Technical analysis vs SPX500 suggests PFE may be forming a bottom, but strong buyer signals are still absent. Read the full article on Seeking AlphaAktieägarnas avkastning
| PFE | US Pharmaceuticals | US Marknad | |
|---|---|---|---|
| 7D | 2.3% | 5.0% | 1.1% |
| 1Y | 11.1% | 44.3% | 28.7% |
Avkastning vs industri: PFE presterade sämre än US Pharmaceuticals branschen som gav 44.3 % under det senaste året.
Avkastning vs Marknaden: PFE presterade sämre än US marknaden som gav 28.7 % under det senaste året.
Prisvolatilitet
| PFE volatility | |
|---|---|
| PFE Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: PFE har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: PFE s veckovolatilitet ( 3% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1849 | 75,000 | Albert Bourla | www.pfizer.com |
Pfizer Inc. upptäcker, utvecklar, tillverkar, marknadsför, distribuerar och säljer biofarmaceutiska produkter i USA och internationellt. Verksamheten bedrivs inom tre segment: Biopharma, PC1 och Pfizer Ignite. Företaget erbjuder produkter inom internmedicin, inklusive produkter för kardiovaskulära metaboliska sjukdomar under varumärket Eliquis, migränprodukter under varumärkena Nurtec ODT/Vydura och Zavzpret, vacciner under varumärkena Prevnar-familjen, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac och Trumenba samt Paxlovid för behandling av COVID-19.
Pfizer Inc. Sammanfattning av grunderna
| PFE grundläggande statistik | |
|---|---|
| Börsvärde | US$147.62b |
| Vinst(TTM) | US$7.48b |
| Intäkter(TTM) | US$63.32b |
19.7x
P/E-förhållande2.3x
P/S-förhållandeÄr PFE övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| PFE resultaträkning (TTM) | |
|---|---|
| Intäkter | US$63.32b |
| Kostnad för intäkter | US$15.96b |
| Bruttovinst | US$47.36b |
| Övriga kostnader | US$39.88b |
| Intäkter | US$7.48b |
Senast redovisade vinst
Mar 29, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 1.31 |
| Bruttomarginal | 74.80% |
| Nettovinstmarginal | 11.81% |
| Skuld/egenkapitalförhållande | 71.6% |
Hur har PFE utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
6.6%
Aktuell utdelningsavkastning131%
UtbetalningskvotGer PFE en tillförlitlig utdelning?
Se PFE utdelningshistorik och jämförelsetal| Pfizer datum för utdelning | |
|---|---|
| Ex utdelningsdag | May 08 2026 |
| Utbetalningsdag för utdelning | Jun 12 2026 |
| Dagar till Ex-utdelning | 17 days |
| Dagar till utdelningsdag | 18 days |
Ger PFE en tillförlitlig utdelning?
Se PFE utdelningshistorik och jämförelsetalFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/24 23:31 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/29 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Pfizer Inc. bevakas av 44 analytiker. 26 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |